Chronic Non-infectious Uveitis in Patients with Juvenile Idiopathic Arthritis

REFERENCES

• Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767–778.
   PubMed Web of Science ®Google Scholar
• Espinosa M, Gottlieb BS. Juvenile idiopathic arthritis. Pediatr Rev. 2012;33:303–313.
   PubMedGoogle Scholar
• Lee FF, Foster CS. Pharmacotherapy of uveitis. Expert Opin Pharmacother. 2010;11:1135–1146.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Simonini G, Frediani B, et al. Treatment strategies for childhood noninfectious chronic uveitis: an update. Expert Opin Investig Drugs. 2012;21:1–6.
   PubMed Web of Science ®Google Scholar
• Pato E, Munoz-Fernandez S, Francisco F, et al. Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Semin Arthritis Rheum. 2011;40:314–323.
   PubMed Web of Science ®Google Scholar
• Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113:308–314.
   PubMed Web of Science ®Google Scholar
• Kahn P. Juvenile idiopathic arthritis – an update on pharmacotherapy. Bull NYU Hosp Jt Dis. 2011;69:264–276.
   PubMedGoogle Scholar
• Rabinovich CE. Treatment of juvenile idiopathic arthritis-associated uveitis: challenges and update. Curr Opin Rheumatol. 2011;23:432–436.
   PubMed Web of Science ®Google Scholar
• Pilly B, Heath G, Tschuor P, et al. Overview and recent developments in the medical management of paediatric uveitis. Expert Opin Pharmacother. 2013; 14:1787–1795.
   Google Scholar
• Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA. 2005; 294:1671–1684.
   Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Semeraro F, Arcidiacono B, Nascimbeni G, et al. Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis. Drug Des Devel Ther. 2014;8:341–348.
   PubMed Web of Science ®Google Scholar
• Little JA, Sen ES, Strike H, et al. The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhood. J Rheumatol. 2014;41:136–139.
   PubMed Web of Science ®Google Scholar
• Schmeling H, Foeldvari I, Horneff G. A39: efficacy and safety of methotrexate in oligoarticular persistent juvenile idiopathic arthritis. Arthritis Rheumatol. 2014;66 Suppl 11:S59.
   Google Scholar
• Papadopoulou C, Kostik M, Bohm M, et al. Methotrexate therapy may prevent the onset of uveitis in juvenile idiopathic arthritis. J Pediatr. 2013;163:879–884.
   PubMed Web of Science ®Google Scholar
• Magli A, Forte R, Navarro P, et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol. 2013; 251:1601–1606.
   Google Scholar
• William M, Faez S, Papaliodis GN, et al. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect. 2012;2:231–233.
   PubMedGoogle Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785–796 e783.
   PubMed Web of Science ®Google Scholar
• Saeed MU, Raza SH, Goyal S, et al. Etanercept in methotrexate-resistant JIA-related uveitis. Semin Ophthalmol. 2014;29:1–3.
   PubMed Web of Science ®Google Scholar
• Anink J, Otten MH, Prince FH, et al. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register. Rheumatology. 2013;52:712–717.
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Foeldvari I, Edelsten C, et al. Proposed outcome measures for prospective clinical trials in juvenile idiopathic arthritis-associated uveitis: a consensus effort from the multinational interdisciplinary working group for uveitis in childhood. Arthritis Care Res (Hoboken). 2012;64:1365–1372.
   PubMed Web of Science ®Google Scholar
• Lerman MA, Burnham JM, Chang PY, et al. Response of pediatric uveitis to tumor necrosis factor-alpha inhibitors. J Rheumatol. 2013;40:1394–1403.
   PubMed Web of Science ®Google Scholar
• Zannin ME, Birolo C, Gerloni VM, et al. Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry. J Rheumatol. 2013;40:74–79.
   PubMed Web of Science ®Google Scholar
• Garcia-De-Vicuna C, Diaz-Llopis M, Salom D, et al. Usefulness of adalimumab in the treatment of refractory uveitis associated with juvenile idiopathic arthritis. Mediators Inflamm. 2013;2013:560632.
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, Salom D, Garcia-de-Vicuna C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575–1581.
   PubMed Web of Science ®Google Scholar
• Adan A, Mesquida M, Llorenc V, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251:2627–2632.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Benton D, et al. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials. 2014;15:14.
   PubMed Web of Science ®Google Scholar
• Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014;22:96–101.
   PubMed Web of Science ®Google Scholar
• Artornsombudh P, Pistilli M, Foster CS, et al. Factors predictive of remission of new-onset anterior uveitis. Ophthalmology. 2014;121:778–784.
   PubMed Web of Science ®Google Scholar
• Vidqvist KL, Malin M, Varjolahti-Lehtinen T, et al. Disease activity of idiopathic juvenile arthritis continues through adolescence despite the use of biologic therapies. Rheumatology. 2013; 52:1999–2003.
   Google Scholar
• de Boer J, Steijaert A, van den Bor R, et al. development of macular edema and impact on visual acuity in uveitis associated with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2015;23:67–73.
   PubMed Web of Science ®Google Scholar
• Gregory AC 2nd, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013;120:186–192.
   PubMed Web of Science ®Google Scholar
• Magli A, Forte R, Rombetto L, et al. cataract management in juvenile idiopathic arthritis: simultaneous versus secondary intraocular lens implantation. Ocul Immunol Inflamm. 2014;22:133–137.
   PubMed Web of Science ®Google Scholar
• Grajewski RS, Zurek-Imhoff B, Roesel M, et al. Favourable outcome after cataract surgery with IOL implantation in uveitis associated with juvenile idiopathic arthritis. Acta Ophthalmol. 2012;90:657–662.
   PubMed Web of Science ®Google Scholar
• Ozdal PC, Vianna RN, Deschenes J. Visual outcome of juvenile rheumatoid arthritis-associated uveitis in adults. Ocul Immunol Inflamm. 2005;13:33–38.
   PubMed Web of Science ®Google Scholar
• Camuglia JE, Whitford CL, Hall AJ. Juvenile idiopathic arthritis associated uveitis in adults: a case series. Ocul Immunol Inflamm. 2009;17:330–334.
   PubMed Web of Science ®Google Scholar
• Tambralli A, Beukelman T, Weiser P, et al. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol. 2013; 40:1749–1755.
   Google Scholar
• Minden K, Niewerth M, Zink A, et al. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. Rheumatology. 2012;51:1407–1415.
   PubMed Web of Science ®Google Scholar